Screener
Mirum Pharmaceuticals, Inc. MIRM Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Exchange and repurchase of 2029 convertible notes | (474,365) | — |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600 | 259,948 | — |
| Proceeds from issuance of common stock pursuant to equity plans | 23,499 | 15,047 |
| Net cash provided by financing activities | 481,517 | 15,047 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | (2,645) | 3,281 |
| Net increase in cash, cash equivalents and restricted cash | 34,297 | 5,674 |
| Cash, cash equivalents and restricted cash at beginning of period | 298,165 | 222,928 |
| Cash, cash equivalents and restricted cash at end of period | $332,462 | $228,602 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cash and cash equivalents, end of period of $332.46M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period increased by 45.4% year-over-year, from $228.6M to $332.46M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period has grown at a 32.6% compound annual growth rate (CAGR), from $128M to $298.17M.
- What does cash and cash equivalents, end of period mean?
- Cash and cash equivalents, end of period
Ask your AI about Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude